InvestorsHub Logo
Followers 484
Posts 60856
Boards Moderated 18
Alias Born 09/20/2001

Re: JB3729 post# 58666

Friday, 04/08/2016 12:37:28 PM

Friday, April 08, 2016 12:37:28 PM

Post# of 462194
So, it appears to be "spin"?

First that they say attacking other than M-1 has previously caused side effects, then they say that 2-73 attacks other than M-1, concluding without a clear logical argument that this "lack of selectivity" will cause side effects.

As far as today’s tie-up goes, Allergan will clearly have studied the muscarinic space before settling on Heptares, which Mr Weir said had the most advanced project. Anavex’s phase II asset ANAVEX 2-73 is a muscarinic agonist, but also agonises the sigma-1 receptor, which Mr Weir said meant that it lacked HTL18318’s selectivity.



http://epvantage.com/Universal/View.aspx?type=Story&id=632030&isEPVantage=yes

Is this a reasonable interpretation of that press release?


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News